{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:54:14Z","timestamp":1783619654186,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11102-022-01227-x","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T15:02:51Z","timestamp":1651676571000},"page":"733-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Glucocorticoid receptor blockers"],"prefix":"10.1007","volume":"25","author":[{"given":"Mark E.","family":"Molitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"1227_CR1","unstructured":"Philibert D, Deraedt R, Teutsch G (1981) RU 38486 a potent antiglucocorticoid in vivo. In: International congress of pharmacology, Tokyo, Japan. p 668"},{"issue":"4","key":"1227_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1210\/jcem-57-4-863","volume":"57","author":"DL Healy","year":"1983","unstructured":"Healy DL, Chrousos GP, Schulte HM, Williams RF, Baulieu EE, Gold PW, Hodgen GD (1983) Pituitary and adrenal responses to the anti-progesterone and anti-glucocorticoid steroid RU 486 in primates. J Clin Endocrinol Metab 57(4):863\u2013865","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1227_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/jcem-59-1-25","volume":"59","author":"X Bertagna","year":"1984","unstructured":"Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F (1984) The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 59(1):25\u201328","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1227_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1210\/jcem-61-3-536","volume":"61","author":"LK Nieman","year":"1985","unstructured":"Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DI (1985) Successful treatment of Cushing\u2019s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61(3):536\u2013540","journal-title":"J Clin Endocrinol Metab"},{"key":"1227_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000314224","volume":"92","author":"F Castinetti","year":"2010","unstructured":"Castinetti F, Conte-Devolx BT (2010) Medical treatment of Cushing\u2019s syndrome: glucocorticoid receptor antagonists and mifepristone. Neuroendocrinology 92:25\u2013130","journal-title":"Neuroendocrinology"},{"issue":"6","key":"1227_CR6","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 97(6):2039\u20132049","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1227_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4158\/EP12149.RA","volume":"19","author":"M Fleseriu","year":"2013","unstructured":"Fleseriu M, Molitch ME, Gross C, Schteingart DE, Vaughan TB 3rd, Biller BM (2013) A new therapeutic approach in the medical treatment of Cushing\u2019s syndrome: glucocorticoid receptor blockade with mifepristone. Endocr Pract 19(2):313\u2013326","journal-title":"Endocr Pract"},{"issue":"10","key":"1227_CR8","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1210\/jc.2014-1843","volume":"99","author":"M Fleseriu","year":"2014","unstructured":"Fleseriu M, Findling JW, Koch CA, Schlaffer S-M, Buchfelder M, Gross C (2014) Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab 99(10):3718\u20133727","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1227_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40842-020-00105-4","volume":"6","author":"DR Brown","year":"2020","unstructured":"Brown DR, East HD, Eilerman BS, Gordon MB, King EE, Knecht LA, Salke B, Samson SL, Yuen KCJ, Yau H (2020) Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations. Clin Diabetes Endocrinol 6(1):18. https:\/\/doi.org\/10.1186\/s40842-020-00105-4","journal-title":"Clin Diabetes Endocrinol"},{"issue":"4","key":"1227_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/cpdd.389","volume":"7","author":"H Hunt","year":"2018","unstructured":"Hunt H, Donaldson K, Strem M, Zann V, Leung P, Sweet S, Connor A, Combs D, Belanoff J (2018) Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase I clinical study. Clin Pharmacol Drug Dev 7(4):408\u2013421","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1227_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.662865","volume":"12","author":"R Pivonello","year":"2021","unstructured":"Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, Mariash CN, Terzolo M, Ellison N, Moraitis AG (2021) Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with Cushing syndrome: results from a prospective, open-label phase 2 study. Front Endocrinol 12:662865. https:\/\/doi.org\/10.3389\/fendo.2021.662865","journal-title":"Front Endocrinol"},{"issue":"6","key":"1227_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/JCP.0000000000001470","volume":"41","author":"HJ Hunt","year":"2021","unstructured":"Hunt HJ, Donaldson K, Strem M, Tudor JC, Sweet-Smith S, Sidhu S (2021) Effect of miricorilant, a selective glucocorticoid receptor modulator, on olanzapine-associated weight gain in healthy subjects a proof-of-concept study. J Clin Psychopharmacol 41(6):632\u2013637","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"1227_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz N, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01227-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01227-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01227-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T09:24:23Z","timestamp":1666430663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01227-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01227-x","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"assertion":[{"value":"20 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author receives consultation honoraria from Corcept and previously received research funding from Corcept as an investigator in the SEISMIC study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}